NASDAQ

XBiotech Inc. (XBIT)

590 Thanks from members

XBiotech Inc. (XBIT) displays cautious sentiment, driven by lower R&D expenses and a Phase II trial for vilamakitug, offset by ongoing net losses, zero revenue, and four consecutive quarters of institutional selling.

Special Briefing

How to Live for 300 Years: The Longevity Sandbox

Explore plasma cleansing, somatic organ swaps, and BCI.

Explore →